Literature DB >> 16199542

Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling.

J Ingles, A Doolan, C Chiu, J Seidman, C Seidman, C Semsarian.   

Abstract

OBJECTIVE: To report the frequency of single and multiple gene mutations in an Australian cohort of patients with hypertrophic cardiomyopathy (HCM).
METHODS: Genetic screening of seven HCM genes (beta-MHC, MyBP-C, cTnT, cTnI, ACTC, MYL2, and MYL3) was undertaken in 80 unrelated probands. Screening was by denaturing high performance liquid chromatography and direct DNA sequencing. Clinical data were collected on all patients and on genotyped family members.
RESULTS: 26 mutations were identified in 23 families (29%). Nineteen probands (24%) had single mutations (11 beta-MHC, 4 MyBP-C, 3 cTnI, 1 cTnT). Multiple gene mutations were identified in four probands (5%): one had a double mutation and the others had compound mutations. Six of 14 affected individuals from multiple mutation families (43%) experienced a sudden cardiac death event, compared with 10 of 55 affected members (18%) from single mutation families (p = 0.05). There was an increase in septal wall thickness in patients with compound mutations (mean (SD): 30.7 (3.1) v 24.4 (7.4) mm; p<0.05).
CONCLUSIONS: Multiple gene mutations occurring in HCM families may result in a more severe clinical phenotype because of a "double dose" effect. This highlights the importance of screening the entire panel of HCM genes even after a single mutation has been identified.

Entities:  

Mesh:

Year:  2005        PMID: 16199542      PMCID: PMC1735926          DOI: 10.1136/jmg.2005.033886

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  106 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

Review 2.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 3.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 4.  Cardiovascular genetic medicine: evolving concepts, rationale, and implementation.

Authors:  Ray E Hershberger
Journal:  J Cardiovasc Transl Res       Date:  2008-05-20       Impact factor: 4.132

Review 5.  Role of animal models in HCM research.

Authors:  Rhian Shephard; Christopher Semsarian
Journal:  J Cardiovasc Transl Res       Date:  2009-08-07       Impact factor: 4.132

6.  A low prevalence of MYH7/MYBPC3 mutations among familial hypertrophic cardiomyopathy patients in India.

Authors:  Murali D Bashyam; Guroji Purushotham; Ajay K Chaudhary; Katika Madhumohan Rao; Vishal Acharya; Tabrez A Mohammad; Hampapathalu A Nagarajaram; Vuppaladadhiam Hariram; Calambur Narasimhan
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

7.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

Review 8.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy.

Authors:  Ray E Hershberger; Jill D Siegfried
Journal:  J Am Coll Cardiol       Date:  2011-04-19       Impact factor: 24.094

9.  Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy.

Authors:  Eric C Wooten; Virginia B Hebl; Matthew J Wolf; Sarah R Greytak; Nicole M Orr; Isabelle Draper; Jenna E Calvino; Navin K Kapur; Martin S Maron; Iftikhar J Kullo; Steve R Ommen; J Martijn Bos; Michael J Ackerman; Gordon S Huggins
Journal:  Circ Cardiovasc Genet       Date:  2012-12-19

10.  Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity?

Authors:  I A W van Rijsingen; J F Hermans-van Ast; Y H J M Arens; S M Schalla; C E M de Die-Smulders; A van den Wijngaard; Y M Pinto
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.